RSV nucleoprotein inhibitors in preclinical to phase II clinical development for respiratory syncytial virus infection
Abstract
1. The RSV N protein is an attractive therapeutic target because it is crucial for viral replication and assembly [1]. The N protein encapsulates the RSV genome, forming a helical structure essenti...
Fields of Study & Subjects
Respiratory viral infections research
SARS-CoV-2 and COVID-19 Research
Virology and Viral Diseases
Publication details
- Journal / source
- Expert Opinion on Investigational Drugs
- Volume
- 35
- Issue
- 3
- Pages
- 189–190
- Publication date
- 7 February 2026
- Language
- EN